Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW’s New Anti-RA Measures Likely to Push Proper Use of Pricy Biologics
The Ministry of Health, Labor and Welfare (MHLW) is set to step up its efforts to promote the proper use of biologics for rheumatoid arthritis (RA) as its report for new anti-RA measures is expected to stress the need to…
To read the full story
Related Article
- Reduce Dose, or Discontinue Biologics for Patients with Low RA Disease Activity: Report
July 9, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
- MHLW Proposes Discussing Proper Use of High-Cost Biologics in Preparation for Revision of RA Measures
April 27, 2018
- MHLW’s Panel to Discuss First Revision of Anti-RA Measures in 7 Years; Proper Use of Biologics to Be a Focus
March 28, 2018
REGULATORY
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
- 679 Safety Reports Logged for Regenerative Medical Products in 2H FY2025
August 21, 2026
- Japan Panel to Discuss Approval of 6 NMEs, Leqembi SC on Aug. 26
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…